Article

Statin use and the risk of Clostridium difficile in academic medical centres

Department of Epidemiology and Community Health, Virginia Commonwealth University, School of Medicine, 830 E. Main Street, RM 5010, P.O. Box 980212, Richmond, VA 23298-0212, USA
Gut (Impact Factor: 13.32). 03/2012; 61(11):1538-42. DOI: 10.1136/gutjnl-2011-301378
Source: PubMed

ABSTRACT To estimate the possible relationship between statin use and the risk of healthcare facility onset Clostridium difficile.
Patients over 18 years of age admitted to hospitals contributing data to the University HealthSystem Consortium between 2002 and 2009 were eligible. Patients with the ICD-9-CM code 008.45 who received a minimum 3-day course of either metronidazole or oral vancomycin on/after day 5 of admission were considered incident cases of C difficile infection. 31 472 incident cases of C difficile infection were identified and matched to five controls, on hospital, year/quarter of admission date, and age ±10 years (N=78 096). Patients who were administered one drug in the statin class (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin or simvastatin) before the index date were considered to be exposed. Conditional logistic regression modelling provided adjusted odds ratios and 95% CI.
Compared with non-users, users of any drug within the statin class were 0.78 times less likely to develop C difficile infection in the hospital (95% CI 0.75 to 0.81) adjusting for potential confounders. Differences in estimates for specific statins were minimal. Niacin, fibrates and selective cholesterol absorption inhibitors showed no association with the risk of C difficile infection.
Our data were consistent with a growing body of literature demonstrating a reduced risk of infections with statin use. Statins' pleiotropic properties may provide protection against C difficile infection.

0 Followers
 · 
90 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clostridium difficile infection (CDI) is increasing in all regions of the world where sought. There is no gold standard for diagnosis of CDI, with available tests having limitations. Prevention of CDI will be seen with antibiotic stewardship, improved disinfection of hospitals and nursing homes, chemo- and immuno-prophylaxis and next generation probiotics. The important therapeutic agents are oral vancomycin and fidaxomicin with metronidazole being used only in mild cases or when oral therapy cannot be given. Current therapy of CDI for 10 days is associated with high rate of recurrence that may be prevented by prolonging initial therapy. Future treatment strategies will focus on drugs that inhibit C. difficile, reduce toxin activity and inflammation in the gut, and improve colonic flora diversity.
    Expert Review of Gastroenterology and Hepatology 07/2014; 8(8):1-12. DOI:10.1586/17474124.2014.939630 · 2.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Clostridium difficile infection (CDI) is increasingly recognized as an important community acquired pathogen causing disease (CA-CDI). Vitamin D [25(OH)D] has immune modulatory effects and plays an important role in intestinal immunity. The role of vitamin D in CA-CDI has not been examined previously.Methods This was a single referral center case¿control study. Cases comprised of all patients with CA-CDI who had a serum 25(OH)D measured within 12 months prior to infection. Controls were drawn from patients who had 25(OH)D checked and matched based on age, gender, race and health status. Serum 25(OH)D was stratified as¿<¿15 ng/mL, 15-30 ng/mL or¿>¿30 ng/mL. Regression models adjusting for potential confounders were used to define independent association between vitamin D and CA-CDI.ResultsWe identified 58 matched case¿control pairs (66% women; 85% Caucasian). The mean age was 62 years. The mean serum 25(OH)D level was significantly lower in CA-CDI cases compared to controls (28.5 ng/mL vs. 33.8 ng/mL, p¿=¿0.046). Cases had higher rate of antibiotic exposure and more comorbidity. Serum 25(OH)D¿<¿15 ng/mL was associated with an increased risk of CA-CDI on univariate (Odds ratio (OR) 5.10, 95% confidence interval (CI) 1.51 ¿ 17.24) and multivariate analysis (OR 3.84, 95% CI 1.10 ¿ 13.42). Vitamin D levels between 15-30 ng/mL did not modify disease risk.Conclusions Low serum 25(OH)D¿<¿15 ng/mL was associated with increased risk of CA-CDI. This suggests vitamin D may have a role in determining susceptibility to CA-CDI.
    BMC Infectious Diseases 12/2014; 14(1):661. DOI:10.1186/s12879-014-0661-6 · 2.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clostridium difficile infection (CDI) is a major public health problem worldwide with significant morbidity and mortality that is spread by spores and fecal oral transmission. A variety of risk factors have been identified. Some risk factors such as age, are not amenable to change, while others such as antimicrobial utilization have resulted in broadly implemented antimicrobial stewardship programs. New risk factors are emerging such as proton pump inhibitor (PPI) use, irritable bowel disease (IBD) and obesity, with others yet to be determined. Prevention of spread of CDI is imperative, since therapy remains imperfect. We review established and emerging risks for CDI and offer potential preventative strategies with the use of a multidisciplinary CDI prevention bundle checklist.
    Expert Review of Anti-infective Therapy 08/2014; 12(9). DOI:10.1586/14787210.2014.942284 · 2.28 Impact Factor

Full-text (2 Sources)

Download
43 Downloads
Available from
May 27, 2014